Difference between substrate and inducers in MRR
In the context of MRR (Mismatch Repair), here's a quick distinction:
- Substrate: the DNA molecule (or specific mismatched base pairs/insertion-deletion loops) that MRR acts upon - i.e., the physical target being recognized and repaired.
- Inducers: signals or agents that upregulate/activate the MRR pathway - e.g., DNA-damaging agents like alkylating drugs or oxidative stress that increase expression of MRR genes (MLH1, MSH2, etc.).
Searching sources...
Reading File
Searching the Web
substrate vs inducers mismatch repair MRR DNA repair
I notice the web search results are all about MMR = DNA Mismatch Repair. However, I want to make sure I'm answering the right context. "MRR" could also refer to contexts in pharmacology or biochemistry. Let me check the medical library for more context, but first - the web results clearly point to DNA Mismatch Repair. Let me also consider: could "MRR" mean something in enzyme kinetics (substrate vs inducer in Michaelis-Menten)? Or in a pharmacology context (mixed-function oxidase inducers)?
Finding Sources
Finding Sources
The textbook library doesn't have a direct section on substrates vs inducers in MMR. The web results clearly confirm the DNA Mismatch Repair context. Let me provide a thorough, accurate answer.
Substrate vs. Inducers in MMR (DNA Mismatch Repair)
These are two distinct concepts within the MMR pathway:
Substrate (of MMR)
The substrate is the DNA structure that the MMR machinery physically recognizes and acts upon. Specifically:
| Substrate Type | Example | Recognized by |
|---|---|---|
| Base-base mismatches | G:T, A:C, G:G | MutSα (MSH2-MSH6 heterodimer) |
| Small insertion-deletion loops (IDLs) 1-2 nt | 1-nt loop | MutSα (MSH2-MSH6) |
| Larger IDLs (2-13 nt) | 2-13 nt loop | MutSβ (MSH2-MSH3 heterodimer) |
| Hemi-methylated DNA | Newly synthesized strand | Used to distinguish template from new strand (in bacteria) |
- The substrate is the physical DNA molecule - usually a mismatched duplex with one strand nicked (to indicate the "wrong" strand for repair).
- In vitro assays use a hemi-methylated plasmid with a single mismatch as the canonical substrate, where repair results in excision on the unmethylated (newly synthesized) strand.
- Chemotherapy-induced lesions can also become substrates: for example, FdUrd (5-fluorouracil) mispairs are recognized by MutSα as substrates for MMR.
Key point: the substrate is what MMR repairs - it is the input/target molecule.
Inducers of MMR
Inducers are agents or signals that stimulate or upregulate the expression of MMR genes or increase MMR activity. They do not necessarily get repaired themselves - rather, they trigger the pathway.
| Inducer | Mechanism |
|---|---|
| Alkylating agents (e.g., temozolomide, MNNG) | Produce O⁶-methylguanine lesions; MMR recognizes the mismatch but cannot repair it (futile cycling → apoptosis signal) |
| Oxidative stress / ROS | Causes 8-oxoguanine lesions; can be recognized by MMR |
| DNA damaging chemotherapy (cisplatin, 5-FU) | Cisplatin-GG adducts recognized by MutSα; 5-FU creates FdU:A mispairs |
| Replication errors at microsatellites | Increased slippage in repetitive sequences induces MMR activity |
An important nuance: alkylating agents like MNNG are often called MMR "inducers" or "activators" because they cause MMR proteins to engage - but when MMR cannot actually excise the offending lesion (e.g., O⁶-MeG), the pathway cycles futilely and instead triggers apoptotic signaling (via ATM/ATR → CHK1/CHK2 → p53). This is why MMR-deficient tumors are resistant to alkylating agents.
Key Difference Summary
| Substrate | Inducer | |
|---|---|---|
| Definition | The DNA structure MMR recognizes and repairs | Agent/signal that activates or upregulates MMR |
| Role | Input to the repair reaction | Upstream trigger |
| Examples | G:T mismatch, IDL, hemi-methylated DNA, FdU:A pair | Alkylating agents, cisplatin, oxidative stress |
| Fate | Gets excised and replaced by correct nucleotides | May or may not itself be repaired; triggers pathway activity |
| Proteins involved | MutSα/MutSβ bind directly to substrate DNA | Increase transcription/activity of MLH1, MSH2, MSH6, PMS2 etc. |
Clinical Relevance
- Tumors with MMR deficiency (dMMR/MSI-H) cannot process substrates - this leads to microsatellite instability and accumulation of mutations.
- These tumors are also resistant to alkylating inducers (e.g., temozolomide) because the futile cycling/apoptosis signal is absent.
- dMMR is predictive of response to immune checkpoint inhibitors (pembrolizumab is FDA-approved for dMMR solid tumors), because the high mutational burden creates neoantigens.
This is a shared conversation. Sign in to Orris to start your own chat.